Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (51-60 of 186) with videos related to

Pageof 19
Sort By:
Cancer Science|February 7, 2019
Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumorsTaito Esaki, Fumihiko Hirai, Akitaka Makiyama, et al.
Cancer Science|July 15, 2022
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumorsToshihiko Doi, Kohei Shitara, Takashi Kojima, et al.
Investigational New Drugs|March 17, 2015
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experienceAkihito Kawazoe, Kohei Shitara, Shota Fukuoka, et al.
International Journal of Clinical Oncology|March 21, 2023
Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective studyRyosuke Kumanishi, Shigenori Kadowaki, Seiichiro Mitani, et al.
BMC Cancer|April 18, 2015
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancerAkihito Kawazoe, Kohei Shitara, Shota Fukuoka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 3, 2018
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancerAkihito Kawazoe, Kohei Shitara, Yasutoshi Kuboki, et al.
Japanese Journal of Clinical Oncology|May 16, 2020
A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study)Tomohiro Kadota, Yuichiro Tsukada, Masaaki Ito, et al.
Japanese Journal of Clinical Oncology|April 17, 2018
Feasibility study of cancer genome alterations identified by next generation sequencing: ABC studyYoichi Naito, Hideaki Takahashi, Kohei Shitara, et al.
BMC Cancer|December 29, 2019
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancerDaisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, et al.
British Journal of Cancer|February 27, 2020
Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancerHideaki Bando, Yoshinori Kagawa, Takeshi Kato, et al.
Pageof 19

Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Cancer Science|February 7, 2019
Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumorsTaito Esaki, Fumihiko Hirai, Akitaka Makiyama, et al.
Cancer Science|July 15, 2022
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumorsToshihiko Doi, Kohei Shitara, Takashi Kojima, et al.
Investigational New Drugs|March 17, 2015
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experienceAkihito Kawazoe, Kohei Shitara, Shota Fukuoka, et al.
International Journal of Clinical Oncology|March 21, 2023
Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective studyRyosuke Kumanishi, Shigenori Kadowaki, Seiichiro Mitani, et al.
BMC Cancer|April 18, 2015
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancerAkihito Kawazoe, Kohei Shitara, Shota Fukuoka, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 3, 2018
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancerAkihito Kawazoe, Kohei Shitara, Yasutoshi Kuboki, et al.
Japanese Journal of Clinical Oncology|May 16, 2020
A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study)Tomohiro Kadota, Yuichiro Tsukada, Masaaki Ito, et al.
Japanese Journal of Clinical Oncology|April 17, 2018
Feasibility study of cancer genome alterations identified by next generation sequencing: ABC studyYoichi Naito, Hideaki Takahashi, Kohei Shitara, et al.
BMC Cancer|December 29, 2019
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancerDaisuke Kotani, Yasutoshi Kuboki, Satoshi Horasawa, et al.
British Journal of Cancer|February 27, 2020
Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancerHideaki Bando, Yoshinori Kagawa, Takeshi Kato, et al.
Pageof 19